GSK plc announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecologic cancers may experience. The survey, which was conducted by ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

Mark David Hartley outlines a strategy he’d use to aim for a second income that gets bigger over time, by investing just £10 a day.

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...

GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...